• Manufacturer of advanced intermediates for patented APIs; supplier to marquee customers in regulated markets
  • Contract manufacturer of APIs for patented drugs
  • 3 USFDA approved plants (2 in Spain, 1 in Mexico)
  • More than 47 DMF’s, 20 COS and franchise position in anti-ulcer segment
  • The Fund has exited this investment.
Scroll to top